Evidence map›Paper›PMID 25379408›Full record

ArticleLeukemia research reports2014

The BH3-mimetic ABT-737 effectively kills acute myeloid leukemia initiating cells.

Denis V Baev, Janusz Krawczyk, Michael O׳Dwyer, Eva Szegezdi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia research reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Denis V BaevApoptosis Research Centre, School of Natural Sciences, National University of Ireland, Biosciences, Dangan, Galway, Ireland.
Janusz KrawczykDepartment of Hematology, University Hospital Galway, Newcastle Road, Galway, Ireland.
Michael O׳DwyerApoptosis Research Centre, School of Natural Sciences, National University of Ireland, Biosciences, Dangan, Galway, Ireland ; Department of Hematology, University Hospital Galway, Newcastle Road, Galway, Ireland.
Eva SzegezdiApoptosis Research Centre, School of Natural Sciences, National University of Ireland, Biosciences, Dangan, Galway, Ireland.
National University of Ireland · IEUniversity Hospital Galway · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The anti-apoptotic proteins Bcl-XL and Bcl-2 are abundantly expressed in hematopoietic stem cells and/or progenitor cells. Furthermore, leukemic cells expressing these proteins are enriched in minimal residual disease cell populations. This prompted us to test the BH3-mimetic compound ABT-737 for its ability to eradicate putative leukemic stem cells. ABT-737 demonstrated potent cytotoxic effects in all patient samples tested. The efficacy of ABT-737 against AML blasts and the primitive CD34(+)/CD38(-) population was equal and independent of sensitivity to cytarabine/daunorubicin. These results, together with previously reported synergistic effects of ABT-737 with chemotherapeutics make BH3-mimetics promising candidates for future AML treatment regimens.

Indexed as

ABT-737Acute myeloid leukemiaBH3-mimeticCD34+/CD38−Putative leukemic stem cells

Identifiers

PMID25379408
PMCPMC4216386
OpenAlexW1998718877

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.